Raltegravir plus Ritonavir-Boosted Darunavir

NEAT001/ANRS 143 Trial
Darunavir/r + Raltegravir versus Darunavir/r + TDF-FTC NEAT001/ANRS143: Study Design

Study Design: NEAT001/ANRS 143

- **Background**: Randomized, open-label, non-inferiority trial study to evaluate the efficacy and safety of a NtRTI-sparing regimen of raltegravir and boosted darunavir vs. combination tenofovir DF-emtricitabine and boosted darunavir.

- **Inclusion Criteria (n = 805)**
  - Age ≥18 years
  - Antiretroviral-naïve
  - HIV RNA >1,000 copies/mL
  - CD4 <500 cells/mm³
  - No major resistance mutations

- **Treatment Arms**
  - Darunavir 800 mg QD + Ritonavir 100 mg QD + Raltegravir 400 mg BID
  - Darunavir 800 mg QD + Ritonavir 100 mg QD + TDF-FTC QD

Darunavir/r + Raltegravir versus Darunavir/r + TDF-FTC NEAT001/ANRS143: Result

Week 96: Treatment Failure, by Baseline HIV RNA*


*Kaplan-Meier estimates of proportion of patients reaching endpoints*
Darunavir/r + Raltegravir versus Darunavir/r + TDF-FTC NEAT001/ANRS143: Result

Week 96: Treatment Failure, by Baseline CD4 Count*

*Kaplan-Meier estimates of proportion of patients reaching endpoints

Darunavir/r + Raltegravir versus Darunavir/r + TDF-FTC
NEAT001/ANRS143: Result

Week 96: Treatment Failure, by HIV RNA and CD4 Count (combined effects)

Darunavir/r + Raltegravir versus Darunavir/r + TDF-FTC NEAT001/ANRS143: Result

Week 96: Change in Lipids from Baseline

Week 96: Change in Creatinine Clearance from Baseline

Darunavir/r + Raltegravir versus Darunavir/r + TDF-FTC
NEAT001/ANRS143: Substudy Result

Week 48: Changes in Spine and Hip Bone Mineral Density from Baseline

**Genotype Resistance Testing in NEAT001/ANRS143**

<table>
<thead>
<tr>
<th>Resistance Testing and Results</th>
<th>RAL + DRV/r (n = 401)</th>
<th>DRV/r + TDF/FTC (n = 404)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients who underwent genotype resistance testing at virological failure</td>
<td>29</td>
<td>13</td>
</tr>
<tr>
<td>Major resistance mutations detected</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Reverse transcriptase</td>
<td>1*</td>
<td>0</td>
</tr>
<tr>
<td>Protease</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Integrase</td>
<td>5**</td>
<td>0</td>
</tr>
</tbody>
</table>

*K65R mutation; **N155H mutation

Interpretation: “Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL.”
Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*